Pharmaceutical Companies Spend More After Phase II
作者: 整理时间:2005-10-27
10/26/2005
Research Triangle Park, NC -- When a brand reaches Phase II of development, pharmaceutical companies begin to pour more money into commercial spending, according to a recent report, "Pharmaceutical Product Commercialization: Pre-Clinical to Phase III Resource Allocation" published by Cutting Edge Information.
One of the key trends observed in this report is that commercial spending and staffing stays in check in Pre-Clinical through Phase I development. Companies tend to be more cautious with staffing and funds during these early stages regardless of whether they are promoting a future blockbuster drug or a small, niche brand.
However, once developers begin to feel comfortable with their drugs' clinical performance, commercial outlook, and peak sales projections (this usually happens around Phase II), spending and staffing rise substantially. At this point it becomes obvious which companies plan to promote a blockbuster and which companies are expecting to release a smaller brand. The difference in commercial spending between average blockbuster and niche brands in Phase II is $7.29 million.
"By Phase II, when drug developers begin to understand their brands' clinical and commercial strengths and weaknesses, companies tend to spend more in line with their drug's commercial prospects or shortcomings," says Jon Hess, project team leader at Cutting Edge Information.
"Pharmaceutical Product Commercialization: Pre-Clinical to Phase III Resource Allocation," available at http://www.PharmaCommercialization.com, includes more than 350 metrics, more than 145 charts and graphics, and detailed analysis of 16 brands' commercial spending and staffing levels from Pre-Clinical through Phase III development. The report also details resource allocation processes, marketing team structures and portfolio decision-making processes from several of the industry's top companies including Eli Lilly, Novartis, Sanofi-Aventis and Bristol-Myers Squibb.
To download a free summary of "Pharmaceutical Product Commercialization: Pre-Clinical to Phase III Resource Allocation," visit http://www.PharmaCommercialization.com.
Jon Hess is a project team leader with Cutting Edge Information. Mr. Hess' expertise includes clinical trials operations, early-stage drug development and commercialization, medical publications, manufacturing quality control and the generic drug market. His research has bolstered portfolio planning and optimization at several top pharmaceutical companies.
SOURCE: Cutting Edge Information
|
